Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec SE    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report  
Real-time Quote. Real-time Tradegate - 07/17 03:59:22 pm
25.55 EUR   -0.12%
07/16EVOTEC : expands its iPSC discovery platform
AQ
07/15EVOTEC : Expands its ipsc discovery platform
EQ
07/12EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Evotec SE

Evotec specializes in research and development services for the pharmaceutical and biotechnological industries. The group's activity is organized around 3 areas:

- development of broadband screening systems;

- research and development of pharmaceutical products: for the neurologic, oncologic, inflammatory diseases treatment;

- other: target identification, pharmacological tests development, broadband screening services, etc.

Net sales are distributed geographically as follows: Germany (11.9%), the United States (37.8%), France (23.4%), the United Kingdom (10.4%) and other (16.5%).

Number of employees : 2 178 people.
Sales per Businesses
20162017Delta
EUR (in Million)%EUR (in Million)%
EVT Execute137.8583.8%213.7883% +55.08%
EVT Innovate26.6616.2%43.8517% +64.51%
Sales per Regions
20162017Delta
EUR (in Million)%EUR (in Million)%
Europe97.0659%---
United States65.8040%97.4937.8% +48.15%
Japan and Rest of the World1.651%---
Germany--30.7511.9%-
United Kingdom--26.8210.4%-
France--60.1823.4%-
Rest of the World--42.3916.5%-
Managers
NameAgeSinceTitle
Werner Lanthaler, PhD512009Chief Executive Officer
Wolfgang Plischke, PhD682014Chairman-Supervisory Board
Craig L. Johnstone-2019Chief Operating Officer & Member-Management Board
Enno Spillner, MBA492016Chief Financial Officer
Cord E. Dohrmann, PhD552010Chief Scientific Officer
Claus Tycho Bræstrup, MD742013Independent Member-Supervisory Board
Bernd Hirsch492013Vice Chairman-Supervisory Board
Iris Löw-Friedrich MD, PhD592014Independent Member-Supervisory Board
Elaine Sullivan, PhD592015Member-Supervisory Board
Michael Shalmi MD, MBA542017Member-Supervisory Board
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Stock A 1 149,853,449 120,499,632 80.4% 249,915 0.2% 80.4%
Shareholders
NameEquities%
Novo Nordisk Fonden 14,767,926 9.91%
Roland Oetker 13,510,453 9.06%
Allianz Global Investors GmbH 7,222,659 4.85%
DWS Investment GmbH 6,278,449 4.21%
Norges Bank Investment Management 3,700,512 2.48%
The Vanguard Group, Inc. 3,491,451 2.34%
Deka Investment GmbH 2,366,512 1.59%
Goldman Sachs Asset Management LP 2,207,522 1.48%
BlackRock Asset Management Deutschland AG 2,205,535 1.48%
Principal Global Investors LLC 1,843,682 1.24%
Holdings
NameEquities%Valuation
Evotec SE (EVT) 249,9150.17%4,961,013 USD
Markets and indexes
- Börse Frankfurt
- Prime Standard
- MDAX /
Stock Exchange Codes
- Bloomberg Code :  EVT.NM
- Reuters Code :  EVTG.F
- Datastream Code :  D:EVT
Company contact information
Evotec SE
Manfred Eigen Campus Essener Bogen 7
DE-22419 Hamburg, Hamburg
Germany

Phone : +49 (0) 40 5 60 81 0
Fax : +49 (0) 40 5 60 81 222
Internet : http://www.evotec.com
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
EVOTEC SE47.31%4 217
IQVIA HOLDINGS INC34.78%31 409
LONZA GROUP32.31%25 111
CELLTRION, INC.--.--%20 827
INCYTE CORPORATION25.62%17 419
EXACT SCIENCES CORPORATION82.17%15 001
SEATTLE GENETICS, INC.11.39%10 516
SAGE THERAPEUTICS INC88.18%9 699
IONIS PHARMACEUTICALS INC25.53%9 184
QIAGEN16.26%9 000
ICON PLC16.18%8 080
BIO-TECHNE CORP45.49%7 895
ALNYLAM PHARMACEUTICALS, INC.1.82%7 821
GALAPAGOS91.10%7 729
GALAPAGOS NV (ADR)86.13%7 729
CHARLES RIVER LABORATORIES INTL. INC20.27%6 655
PRA HEALTH SCIENCES INC7.05%6 401
NEKTAR THERAPEUTICS1.03%5 845
HANGZHOU TIGERMED CONSULTING CO LTD--.--%5 786
SYNEOS HEALTH INC23.79%5 040
BLUEPRINT MEDICINES CORP75.74%4 597
Connections : Evotec SE
ERT, Inc. /PA/
SYNLAB Ltd.
Momentum Gruppen A/S
German Chemical Industry Fund
Bayer Real Estate GmbH
University of Hohenheim
Paul Ehrlich-Foundation
Bayer Innovation GmbH
Technology Academy Finland
European Chemical Industry Council
Bundesverband der Deutschen Industrie e.V.
German Asia Pacific Business Association
Robert Koch Stiftung eV
Walter Siegenthaler Gesellschaft
Xellia Holdco A/S
IOLTECH SA
Cimex Medical Innovations LC
Helmholtz-Gemeinschaft Deutscher Forschungszentren eV
Bankinvest Biomedical Venture
Refugees International, Inc.
The Royal Danish Scientific Society
Evotec (UK) Ltd.
Vital Voices Global Partnership, Inc.
Bertelsmann, Inc.
Penguin Random House LLC
Carrick Therapeutics Ltd.
Penguin Random House Ltd.
IP Group Plc /Venture Capital/
Hoechst Marion Roussel, Inc.
Bayer Technology Services GmbH
Johann Wolfgang Goethe-Universität Frankfurt am Main
Concentro Management AG
Biom Venture Capital GmbH & Co. Fonds KG
FSHD Unlimited Cooperatie Ua
Novo Principal Investments
Eternygen GmbH
Aerocrine AB
SYNLAB International GmbH
ERT Holdco A/S
Ataxion, Inc.
Novo Invest 1 A/S
Topas Therapeutics GmbH